SCHEMBL7570704

SCHEMBL7570704

CCC1OC1(CCCCCCOCc1cccs1)C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.41
TSHR P16473 1/20 0.41
SLC1A3 P43003 1/20 0.38
SLC1A2 P43004 1/20 0.38
SLC1A1 P43005 1/20 0.38
NPC1 O15118 3/20 0.35
MAPK1 P28482 1/20 0.34
RAB9A P51151 2/20 0.33
CYP2C19 P33261 1/20 0.33
KMT2A Q03164 2/20 0.32
MAPT P10636 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
MEN1 O00255 1/20 0.32
HSD17B10 Q99714 1/20 0.32
CYP3A4 P08684 1/20 0.32
TRPM8 Q7Z2W7 1/20 0.32
LMNA P02545 1/20 0.32
POLB P06746 1/20 0.32
KDM4E B2RXH2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7573941 0.84 ALDH1A1 (0.33) ALDH1A1TSHRNPC1MAPK1RAB9A
SCHEMBL7578532 0.82 LMNA (0.32) MAPK1MAPTSMN1; SMN2LMNA
SCHEMBL7571141 0.82 ABCB11 (0.31) MAPK1MAPTLMNA
SCHEMBL8017823 0.81 ABCB11 (0.32) ALDH1A1MAPK1RAB9AKMT2AMAPT
SCHEMBL8016482 0.81 SLC1A3 (0.37) TSHRSLC1A3SLC1A2SLC1A1CYP2C19
SCHEMBL7578722 0.81 ALDH1A1 (0.37) ALDH1A1TSHRRAB9ACYP2C19KMT2A
SCHEMBL7577303 0.81 HDAC4 (0.30)
SCHEMBL8013770 0.79 ALDH1A1 (0.32) ALDH1A1NPC1MAPK1RAB9AKMT2A
SCHEMBL7573938 0.73 MEN1 (0.37) ALDH1A1KMT2AMAPTMEN1CYP3A4
SCHEMBL13419906 0.73 NPC1 (0.57) ALDH1A1TSHRSLC1A3SLC1A2SLC1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020198382-A1 Oxiran carboxylic acids for the treatment of diabetes HORST P.O. WOLF (DE) 2002-12-26 US disclosed
US-6013666-A ANTIDIABETIC AGENTS; SIDE EFFECT REDUCTION Jew, Sang Sup (KR) 2000-01-11 US disclosed
WO-1998000422-A1 OXIRANE CARBOXYLIC ACID DERIVATIVE AND ITS MANUFACTURING METHOD JEW SANG SUP (KR) 1998-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198382-A1 Oxiran carboxylic acids for the treatment of diabetes GPR119, SLC5A2, SLC2A4 ALDH1A1 128/4885TSHR 999/4885SLC1A3 588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.